Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
ROCKVILLE, MD, May 07, 2018 --
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will provide a corporate overview presentation at Deutsche Bank's 43rd Annual Health Care Conference in Boston on May 8, 2018 at 8:00 am (ET).
A webcast of the conference presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of this webcast on its website for 30 days after the conference.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo and DART are trademarks or registered trademarks of MacroGenics, Inc.
###
Contacts: Jim Karrels, Senior Vice President, CFO MacroGenics, Inc. 1-301-251-5172, [email protected] Karen Sharma, Senior Vice President MacDougall Biomedical Communications 1-781-235-3060, [email protected]
